CanSino’s 23% Stock Slump Shows Perils of Chasing Vaccine Hype
- Vaccine maker had rallied 189% on coronavirus vaccine optimism
- No one knows how much the stock is worth, says analyst
This article is for subscribers only.
The air has suddenly come out of a rally in a biotech firm that’s been working with China’s military to develop a coronavirus vaccine.
CanSino Biologics Inc. tumbled as much as 23% in Hong Kong trading on Thursday afternoon, erasing an earlier 16% surge. The stock had almost tripled since announcing on March 4 it was in the process of developing a vaccine. The rally accelerated after the company said on Monday Canada approved its clinical trial application for a vaccine.